In-vitro activity of PD 117 596, a new quinolone, against bacterial isolates from cancer patients.
The in-vitro activity of PD117 596, a new 4-quinolone antimicrobial agent was compared with that of ciprofloxacin against 798 Gram-positive and Gram-negative distinct isolates from cancer patients. PD117 596 was found to have a broad antimicrobial spectrum with excellent activity against the Enterobacteriaceae (MIC90 0.03 mg/l) Acinetobacter spp. (MIC90 0.25 mg/l), Aeromonas spp. (MIC100 0.06 mg/l) and Pseudomonas spp. including Ps. aeruginosa (MIC90 0.5 mg/l). It was also extremely active against Gram-positive micro-organisms particularly Staphylococcus spp. (including methicillin-resistant and coagulase-negative isolates) Bacillus spp. and streptococci. PD117 596 had lower minimal inhibitory concentrations against most isolates tested than ciprofloxacin, the most active currently available 4-quinolone.
Department of Medical Specialties, University of Texas M. D. Anderson Cancer Center, Houston.
K V
KV
Rolston
B
B
LeBlanc
D H
DH
Ho
G P
GP
Bodey
D000890:Anti-Infective Agents / Q000494:pharmacology*; D001419:Bacteria / Q000187:drug effects*; D001424:Bacterial Infections / Q000150:complications* / Q000382:microbiology; D002939:Ciprofloxacin / Q000494:pharmacology; D024841:Fluoroquinolones; D006090:Gram-Negative Bacteria / Q000187:drug effects; D006094:Gram-Positive Bacteria / Q000187:drug effects; D006801:Humans; D008826:Microbial Sensitivity Tests; D009369:Neoplasms / Q000150:complications*; D015363:Quinolones
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D015363:Quinolones; D002939:Ciprofloxacin; C057711:PD-117596